We demonstrated that serum adiponectin level at the time of RA diagnosis represents a surrogate biomarker of early radiographic disease progression in patients fulfilling the new ACR-EULAR 2010 criteria and thus may accurately identify patients at high risk of early joint destruction independent of inflammation, autoantibody status, and metabolic disturbances. Here, ADIPOQ is linked to rheumatoid arthritis.